This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

47/100

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Getting a diagnosis

Topic: Brain proteins, microglia and lab models

Plain-language summary

Plasma phosphorylated Tau217 (pTau217) demonstrated the highest diagnostic accuracy for AD, DLB, and FTD (area under the curve [AUCs]: 0.9, 0.84, and 0.79, respectively). CXCL1 (fractalkine), synaptosomal-associated protein 25 (SNAP25), triggering receptor expressed on myeloid cells 1 (TREM1), β-synuclein, and tyrosine kinase (TEK) are expressed differently in DLB and FTD than AD. Ingenuity pathway analyses revealed astrocytic, synaptic, and inflammatory pathways as shared and distinct mechanisms across these dementia types. Our findings establish plasma pTau217 as a robust diagnostic marker. This study provides new plasma biomarkers for differential diagnosis of dementias with a noninvasive method. HIGHLIGHTS: Plasma pTau217 showed high diagnostic accuracy for AD, DLB, and FTD. CXCL1, SNAP25, TREM1, β-synuclein, and TEK are novel markers distinguishing other dementias from AD. Noninvasive plasma biomarkers enable diagnosis and differentiation of dementias.

What this study adds

Evidence grade: Low

The record lists 248 participants. This study found that plasma phosphorylated Tau217 demonstrated the highest diagnostic accuracy for Alzheimer's disease, dementia with Lewy bodies, and frontotemporal dementia. It also identified new plasma biomarkers that are expressed differently in these dementias, providing a noninvasive method for differential diagnosis.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Gezegen, H., Alaylıoğlu, M., Şahin, E., Swann, O., Veleva, E., Guven, G. S., et al. (2025). Unravelling the plasma proteome: Pioneering biomarkers for differential dementia diagnosis. Alzheimer s & Dementia. https://doi.org/10.1002/alz.70162

Vancouver

Gezegen H, Alaylıoğlu M, Şahin E, Swann O, Veleva E, Guven GS, et al. Unravelling the plasma proteome: Pioneering biomarkers for differential dementia diagnosis. Alzheimer s & Dementia. 2025. doi:10.1002/alz.70162. PMID: 40613333.

BibTeX

@article{gezegen2025-40613333,
  author  = {Gezegen, Haşim and Alaylıoğlu, Merve and Şahin, Erdi and Swann, Owen and Veleva, Elena and Guven, Gamze Senol and Yaman, Ümran and Salih, Dervis A. M. and others},
  title   = {{Unravelling the plasma proteome: Pioneering biomarkers for differential dementia diagnosis}},
  journal = {Alzheimer s \& Dementia},
  year    = {2025},
  doi     = {10.1002/alz.70162},
  pmid    = {40613333},
  url     = {https://doi.org/10.1002/alz.70162}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

How to read this study

Design: our record does not state a study design, so check the methods section of the original before weighing the result.
Size: the record lists 248 participants. Ask whether that is enough for the question, and who they were.
Effect: the record gives no effect size, so the summary above cannot say how large any difference was.

What the evidence grade means here

This page is graded low. alzhub.org assigns the grade automatically from keywords in the abstract, not from reading the paper. Low means the abstract matched neither pattern. It is the default label, and it does not mean the work is poor; many sound lab and imaging papers land here. It can add at most 5 of the 100 points in the study score, and it is a label about design, not a verdict on whether the findings are true.

New to reading papers? Six questions to ask of any Alzheimer’s study · how we score.

Key findings

Plasma phosphorylated Tau217 (pTau217) demonstrated the highest diagnostic accuracy for AD, DLB, and FTD (area under the curve [AUCs]: 0.9, 0.84, and 0.79, respectively).
CXCL1 (fractalkine), synaptosomal-associated protein 25 (SNAP25), triggering receptor expressed on myeloid cells 1 (TREM1), β-synuclein, and tyrosine kinase (TEK) are expressed differently in DLB and FTD than AD.
Ingenuity pathway analyses revealed astrocytic, synaptic, and inflammatory pathways as shared and distinct mechanisms across these dementia types.
Our findings establish plasma pTau217 as a robust diagnostic marker.
This study provides new plasma biomarkers for differential diagnosis of dementias with a noninvasive method.

Why it matters

This study found that plasma phosphorylated Tau217 demonstrated the highest diagnostic accuracy for Alzheimer's disease, dementia with Lewy bodies, and frontotemporal dementia. It also identified new plasma biomarkers that are expressed differently in these dementias, providing a noninvasive method for differential diagnosis.

New to this subject? Start with our plain-English guide: Getting a diagnosis →

Study details

Participants248
Evidence strengthLow

How this study scored 47/100

Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (Alzheimer s & Dementia)
Journal's citation record	2 / 4	Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29)
Study design	0 / 12	No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence	1 / 5	Rated “low” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	4 / 5	2025 — within 3 year(s) of the newest study here
Sample size	2 / 4	248 participants
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	3 / 3	Studied in people (participant count stated)
Randomized / blinded	0 / 2	No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	2 / 7	Cited 8 times (OpenAlex, 2026-10-10)
Citations per year	1 / 5	2.7 citations a year over 3 year(s) since 2025
Impact for its field and year	3 / 6	Cited 5.1× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	2 / 6	Cited by 3 other studies in this library
Still being cited	1 / 4	Cited 8 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	1 / 4	Last-listed author Bedia Samancı: h-index 14 (OpenAlex, whole career)
Institution's track record	2 / 3	University College London: institution h-index 2,029 (OpenAlex)
Multicenter collaboration	2 / 3	OpenAlex lists 9 institution(s) in 4 countries
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 40613333)
Free to read	2 / 2	Free to read
Total	47 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 15.

Later studies that cite this one

3 studies in the alzhub library list this one in their references.

Related studies in Getting a diagnosis from nearby years

Also tagged “cerebrospinal”

820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Getting a diagnosis

See all studies in Getting a diagnosis →